HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Bretoni A, Ferrario L, Foglia E. Clinicoecon Outcomes Res. 2019;11:283–300.
The authors of this paper have advised us that there is a typographical error in one of the headings in Table 4. Table 4 occupies two pages and while being continued from page 292 onto page 293, a wrong table header was recorded. The table heading “Effectiveness profile” should instead be replaced by “Equity aspects” on page 293.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]